908 Stock Overview
Manufactures and sells chemical drugs and biological agents in China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Hunan Jingfeng Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥2.04 |
| 52 Week High | CN¥3.99 |
| 52 Week Low | CN¥1.25 |
| Beta | 0.75 |
| 1 Month Change | 28.30% |
| 3 Month Change | -8.11% |
| 1 Year Change | -28.42% |
| 3 Year Change | -68.32% |
| 5 Year Change | -54.87% |
| Change since IPO | -81.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| 908 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 14.6% | -2.3% | 1.3% |
| 1Y | -28.4% | -11.4% | -9.1% |
Return vs Industry: 000908 underperformed the CN Pharmaceuticals industry which returned -11.4% over the past year.
Return vs Market: 000908 underperformed the CN Market which returned -9.1% over the past year.
Price Volatility
| 908 volatility | |
|---|---|
| 908 Average Weekly Movement | 11.2% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in CN Market | 10.6% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 000908's share price has been volatile over the past 3 months.
Volatility Over Time: 000908's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 572 | Xiang Wu Ye | www.jfzhiyao.com |
Hunan Jingfeng Pharmaceutical Co.,Ltd. manufactures and sells chemical drugs and biological agents in China. The company’s principal product is sodium hyaluronate injection for use in orthopedics and surgery applications.
Hunan Jingfeng Pharmaceutical Co.,Ltd. Fundamentals Summary
| 908 fundamental statistics | |
|---|---|
| Market cap | CN¥1.79b |
| Earnings (TTM) | -CN¥212.92m |
| Revenue (TTM) | CN¥581.41m |
3.1x
P/S Ratio-8.4x
P/E RatioIs 908 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 908 income statement (TTM) | |
|---|---|
| Revenue | CN¥581.41m |
| Cost of Revenue | CN¥179.60m |
| Gross Profit | CN¥401.82m |
| Other Expenses | CN¥614.73m |
| Earnings | -CN¥212.92m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 69.11% |
| Net Profit Margin | -36.62% |
| Debt/Equity Ratio | -382.6% |
How did 908 perform over the long term?
See historical performance and comparison